华仁药业9月24日获融资买入747.89万元，融资余额2.61亿元

Group 1 - On September 24, Huaren Pharmaceutical's stock rose by 1.88%, with a trading volume of 58.77 million yuan [1] - The financing data on the same day showed a financing purchase amount of 7.48 million yuan, a repayment of 6.17 million yuan, resulting in a net financing purchase of 1.31 million yuan [1] - As of September 24, the total balance of margin trading for Huaren Pharmaceutical was 261 million yuan, accounting for 6.79% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of September 20, the number of shareholders for Huaren Pharmaceutical was 40,500, a decrease of 1.46% from the previous period [2] - The average circulating shares per person increased by 1.48% to 29,156 shares [2] - For the first half of 2025, Huaren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2] Group 3 - Since its A-share listing, Huaren Pharmaceutical has distributed a total of 294 million yuan in dividends [3] - In the last three years, the cumulative dividend payout amounted to 49.65 million yuan [3]